Scientific intelligence record
Experience 2.0
GLP-1 receptor agonist
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist investigated in type 2 diabetes and weight management. WPF separates findings by dose, population, indication, comparator, and endpoint so that one result is not generalized to every setting.
Record status
Traceability partial
Last meaningful update: 9/23/2026
Ranked research corpus
500
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Cureus · 2023 Sep · PMID 37854744 · DOI 10.7759/cureus.45421
Type 2 diabetes and glycemia · Cardiovascular outcomes · Safety and tolerability
Diabetes, obesity & metabolism · 2023 Mar · PMID 36314246 · DOI 10.1111/dom.14908
Type 2 diabetes and glycemia · Safety and tolerability
Pediatric obesity · 2021 Oct · PMID 33963681 · DOI 10.1111/ijpo.12799
Weight loss and obesity · Pediatric and adolescent research · Mechanism and pharmacology
BMC endocrine disorders · 2022 Apr 7 · PMID 35392872 · DOI 10.1186/s12902-022-01006-6
Type 2 diabetes and glycemia
Diabetes, obesity & metabolism · 2026 Aug 13 · PMID 42595732 · DOI 10.1111/dom.71204
Type 2 diabetes and glycemia · Mechanism and pharmacology
Obesity research & clinical practice · 2025 Jan-Feb · PMID 39904668 · DOI 10.1016/j.orcp.2025.01.009
Weight loss and obesity
Clinics and research in hepatology and gastroenterology · 2021 May · PMID 33309563 · DOI 10.1016/j.clinre.2020.10.012
MASH and liver
Healthcare (Basel, Switzerland) · 2021 Aug 30 · PMID 34574899 · DOI 10.3390/healthcare9091125
Comparative effectiveness
Clinical and experimental hypertension (New York, N.Y. : 1993) · 2020 Jul 3 · PMID 31610701 · DOI 10.1080/10641963.2019.1676771
Type 2 diabetes and glycemia · Cardiovascular outcomes
African health sciences · 2019 Sep · PMID 32127832 · DOI 10.4314/ahs.v19i3.35
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability
Diabetes research and clinical practice · 2024 Jan · PMID 38061446 · DOI 10.1016/j.diabres.2023.111034
Type 2 diabetes and glycemia · Safety and tolerability · Ongoing development
Diabetes, obesity & metabolism · 2016 Jul · PMID 26936426 · DOI 10.1111/dom.12653
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Endocrine · 2015 Apr · PMID 25115635 · DOI 10.1007/s12020-014-0373-0
Type 2 diabetes and glycemia · Mechanism and pharmacology · Comparative effectiveness
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025 Feb · PMID 39401933 · DOI 10.1016/j.soard.2024.08.037
Weight loss and obesity
Obesity surgery · 2025 Mar · PMID 39885064 · DOI 10.1007/s11695-025-07671-5
Weight loss and obesity
International journal of psychiatry in clinical practice · 2025 Nov · PMID 40849800 · DOI 10.1080/13651501.2025.2549307
Weight loss and obesity
Clinical epidemiology · 2022 · PMID 36510488 · DOI 10.2147/CLEP.S391819
Weight loss and obesity · Safety and tolerability
BMC endocrine disorders · 2019 Jan 7 · PMID 30616638 · DOI 10.1186/s12902-018-0332-5
Cardiovascular outcomes
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017 Feb · PMID 27995594 · DOI 10.1007/s13300-016-0217-4
Type 2 diabetes and glycemia · Comparative effectiveness
Diabetes, obesity & metabolism · 2016 Jul · PMID 26662611 · DOI 10.1111/dom.12617
Weight loss and obesity · Type 2 diabetes and glycemia
Diabetes, obesity & metabolism · 2016 Jul · PMID 26679282 · DOI 10.1111/dom.12623
Weight loss and obesity · Type 2 diabetes and glycemia
Diabetes care · 2015 Jun · PMID 25504028 · DOI 10.2337/dc13-1210
Type 2 diabetes and glycemia · Safety and tolerability
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2011 May-Jun · PMID 21700561 · DOI 10.4158/EP10215.RA
Kidney outcomes · Safety and tolerability
Sleep & breathing = Schlaf & Atmung · 2023 Oct · PMID 36542275 · DOI 10.1007/s11325-022-02768-y
Type 2 diabetes and glycemia · Safety and tolerability
The Journal of clinical endocrinology and metabolism · 2022 Aug 18 · PMID 35833597 · DOI 10.1210/clinem/dgac369
Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Liraglutide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
APA
World Peptide Foundation. (n.d.). Liraglutide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 23, 2026.) https://www.worldpeptidefoundation.org/directory/liraglutide
AMA / Vancouver
World Peptide Foundation. Liraglutide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 23, 2026. https://www.worldpeptidefoundation.org/directory/liraglutide
Featured tiered studies
93
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
12
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
0
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
500
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
93
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
12
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
0
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
3
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Liraglutide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasNo reviewed published evidence records are represented for this peptide yet. This is not evidence that no research exists.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
No reviewed chemistry record is currently represented for this peptide.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
No peptide-specific research chronology has been represented yet.
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No verified published evidence records are currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
A reviewed chemistry record is not currently represented.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
Connections
Connections appear only when they are represented by the project’s underlying records.
No structured peptide-specific connections are currently represented.
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 12 domain conclusions and 93 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Liraglutide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:36 AM
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.